RecruitingPhase 2NCT06087861

5-Day Preoperative Radiation for Soft Tissue Sarcoma

Phase 2 5-Day Preoperative Radiation for Soft Tissue Sarcoma


Sponsor

Stanford University

Enrollment

75 participants

Start Date

Oct 6, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this study is to examine the safety and efficacy of an abbreviated course of preoperative radiation, given over five days, for patients with soft tissue sarcoma of the extremity, trunk or retroperitoneum. This is in contrast to standard preoperative radiation, which is given over 25 days.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is evaluating a shorter, 5-day course of radiation therapy given before surgery for soft tissue sarcoma (a cancer of muscles, fat, and connective tissues). Standard radiation usually takes 5 weeks, and researchers are investigating whether this compressed schedule is just as effective and safe. **You may be eligible if...** - You are 18 or older - You have been diagnosed with soft tissue sarcoma of the arm, leg, trunk, or abdomen (retroperitoneum), confirmed by biopsy - Your doctor has recommended surgery and pre-surgery radiation as part of your standard care - You are in good overall physical condition (KPS ≥ 70 or ECOG 0–2) - You have a life expectancy of at least 6 months **You may NOT be eligible if...** - You have had prior radiation to the area being treated - You are currently participating in another cancer treatment trial - You are planned to receive chemotherapy, targeted therapy, or immunotherapy at the same time as radiation - You are pregnant Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

RADIATIONExternal Beam Radiotherapy

Radiation will be delivered by external beam techniques to the tumor and areas of possible microscopic disease at a dose of 30 Gy divided into 5 equal fractions of 6 Gy (administered over a total of 5 to 10 business day


Locations(1)

Stanford University

Palo Alto, California, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06087861


Related Trials